The biotech firm reported a wider net loss of $9.0 million for Q1 2025 amid rising operating expenses.
Medicus Pharma Ltd. reported a Q1 GAAP loss of $0.31 per share, widening from a prior-year loss as expenses climbed. The company’s net loss totaled $9.0 million, up from $5.1 million in Q1 2025.
Cash and cash equivalents rose to $6.4 million as of March 31, 2026, compared with $4.0 million a year earlier. Operating expenses surged to $8.6 million, driven by higher general and administrative costs of $5.9 million and research and development spending of $2.7 million.
The results reflect increased investment in operations and R&D, though the company’s cash position improved year-over-year.